CO6341626A2 - Proceso para la preparacion de derivados de benzoimidazol-2-il pirimidina - Google Patents

Proceso para la preparacion de derivados de benzoimidazol-2-il pirimidina

Info

Publication number
CO6341626A2
CO6341626A2 CO11000462A CO11000462A CO6341626A2 CO 6341626 A2 CO6341626 A2 CO 6341626A2 CO 11000462 A CO11000462 A CO 11000462A CO 11000462 A CO11000462 A CO 11000462A CO 6341626 A2 CO6341626 A2 CO 6341626A2
Authority
CO
Colombia
Prior art keywords
group
4alkyl
alkyl
preparation
nrarb
Prior art date
Application number
CO11000462A
Other languages
English (en)
Inventor
Cancian Sergio Cesco
Jeffrey S Grimm
Susanne Lochner
Diego Broggini
Tong Xiao
Daniel J Pippel
David C Palmer
Christopher Mapes
Neelakandha Mani
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41426846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6341626(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO6341626A2 publication Critical patent/CO6341626A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención está dirigida a un proceso para la preparación de compuestos de Fórmula (I)en donde cada uno de R1, R2, R3 y R4 se selecciona, independientemente, del grupo que consiste de H, alquilo de C1-4, alquenilo de C2-4, alquinilo de C2-4, fenilo, -CF3, -OCF3, -CN, halo, -NO2, -OC1-4alquilo, -SC1-4alquilo, -S(O)C1-4alquilo, -SO2C1-4alquilo, -C(O)C1-4alquilo, -C(O)fenilo, -C(O)NRaRb, -CO2alquilo de C1-4, -CO2H, - C(O)NRaRb, y -NRaRb; en donde Ra y Rb se selecciona, independientemente, del grupo que consiste de H, alquilo de C1-4, y cicloalquilo de C3-7;X1 es C-Rc; en donde Rc se selecciona del grupo que consiste de H, metilo, hidroximetilo, dimetilaminometilo, etilo, propilo, isopropilo, -CF3, ciclopropilo, y ciclobutilo; y X2 es N;n es 1 ó 2Z se selecciona del grupo que consiste de N, CH, y C(alquilo de C1-4); R6 se selecciona del grupo que consiste de H, alquilo de C1-6, y un cicloalquilo monocíclico; R8 se selecciona del grupo que consiste de H y alquilo de C1-4;R9, R10 y R11 se selecciona, independientemente, del grupo que consiste de H y alquilo de C1-4 y sales farmacéuticamente aceptables, profármacos farmacéuticamente aceptables, y metabolitos farmacéuticamente aceptables de éstos.
CO11000462A 2008-06-30 2011-01-04 Proceso para la preparacion de derivados de benzoimidazol-2-il pirimidina CO6341626A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7675908P 2008-06-30 2008-06-30

Publications (1)

Publication Number Publication Date
CO6341626A2 true CO6341626A2 (es) 2011-11-21

Family

ID=41426846

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11000462A CO6341626A2 (es) 2008-06-30 2011-01-04 Proceso para la preparacion de derivados de benzoimidazol-2-il pirimidina

Country Status (27)

Country Link
US (3) US20100029942A1 (es)
EP (2) EP2303869A2 (es)
JP (2) JP2011526911A (es)
KR (1) KR20110022721A (es)
CN (2) CN103319459A (es)
AR (1) AR072397A1 (es)
AU (1) AU2009267159B2 (es)
BR (1) BRPI0913989A2 (es)
CA (1) CA2729703A1 (es)
CL (1) CL2010001639A1 (es)
CO (1) CO6341626A2 (es)
CR (1) CR20110057A (es)
EA (1) EA020090B1 (es)
EC (1) ECSP11010744A (es)
IL (1) IL210213A (es)
MX (1) MX2011000081A (es)
MY (1) MY157197A (es)
NI (1) NI201000233A (es)
NZ (2) NZ590169A (es)
PE (1) PE20140592A1 (es)
SG (1) SG192446A1 (es)
SV (1) SV2011003789A (es)
TW (2) TWI485147B (es)
UA (1) UA102855C2 (es)
UY (1) UY31951A (es)
WO (1) WO2010002777A2 (es)
ZA (1) ZA201100760B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51423B (en) 2006-03-31 2011-02-28 Janssen Pharmaceutica N.V. BENZOIMIDAZOL-2-IL PYRIMIDINI I KAO PYRAZID MODULATORS HISTAMINSKOG H4 RECEPTOR
ES2538135T3 (es) * 2008-06-30 2015-06-17 Janssen Pharmaceutica N.V. Proceso para la preparación de derivados sustituidos de pirimidina
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
BRPI0913989A2 (pt) 2008-06-30 2015-10-20 Janssen Pharmaceutica Nv processo para preparação de derivados de benzoimidazol-2-il pirirmidina
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
MX2015011688A (es) 2013-03-06 2015-12-07 Janssen Pharmaceutica Nv Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
US9796699B2 (en) 2015-11-03 2017-10-24 Janssen Pharmaceutica Nv Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3005852A (en) 1959-12-22 1961-10-24 Gen Aniline & Film Corp Production of sulfoxides and sulfones
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
GB9422391D0 (en) 1994-11-05 1995-01-04 Solvay Interox Ltd Oxidation of organosulphur compounds
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
DE60125429T2 (de) * 2000-04-24 2007-09-27 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartrat solvat
BR0112712A (pt) 2000-07-21 2003-05-20 Syngenta Partcipations Ag Processo para preparação de 4,6-dimetóxi-2-(metilsulfonil)-1,3-pirimidina
WO2002064096A2 (en) 2001-02-16 2002-08-22 Tularik Inc. Methods of using pyrimidine-based antiviral agents
TWI270542B (en) 2002-02-07 2007-01-11 Sumitomo Chemical Co Method for preparing sulfone or sulfoxide compound
US7432378B2 (en) 2003-09-30 2008-10-07 Janssen Pharmaceutica, N.V. Benzoimidazole compounds
US20060127404A1 (en) * 2003-09-30 2006-06-15 Chichi Huang Hinge core mimetibodies, compositions, methods and uses
CA2560896C (en) * 2004-03-25 2013-06-18 Janssen Pharmaceutica, N.V. Imidazole compounds
ES2530258T3 (es) * 2004-09-27 2015-02-27 Acadia Pharmaceuticals Inc. Síntesis de una forma cristalina de sal tartrato de N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida
US20060281712A1 (en) 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
RS51423B (en) * 2006-03-31 2011-02-28 Janssen Pharmaceutica N.V. BENZOIMIDAZOL-2-IL PYRIMIDINI I KAO PYRAZID MODULATORS HISTAMINSKOG H4 RECEPTOR
EP2004188B1 (en) * 2006-03-31 2010-09-01 Janssen Pharmaceutica NV Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
BRPI0913989A2 (pt) 2008-06-30 2015-10-20 Janssen Pharmaceutica Nv processo para preparação de derivados de benzoimidazol-2-il pirirmidina

Also Published As

Publication number Publication date
UA102855C2 (ru) 2013-08-27
CN102137857A (zh) 2011-07-27
SG192446A1 (en) 2013-08-30
US8835633B2 (en) 2014-09-16
MY157197A (en) 2016-05-13
TWI485147B (zh) 2015-05-21
CN103319459A (zh) 2013-09-25
AR072397A1 (es) 2010-08-25
EP2303869A2 (en) 2011-04-06
NZ590169A (en) 2012-05-25
EP2865678A2 (en) 2015-04-29
US20120178932A1 (en) 2012-07-12
AU2009267159B2 (en) 2014-05-15
NZ599747A (en) 2013-03-28
JP2011526911A (ja) 2011-10-20
IL210213A0 (en) 2011-03-31
WO2010002777A2 (en) 2010-01-07
NI201000233A (es) 2011-11-09
EA020090B1 (ru) 2014-08-29
ZA201100760B (en) 2012-07-25
UY31951A (es) 2010-01-29
US20120184740A1 (en) 2012-07-19
BRPI0913989A2 (pt) 2015-10-20
US20100029942A1 (en) 2010-02-04
KR20110022721A (ko) 2011-03-07
EP2865678A3 (en) 2015-05-27
EA201170114A1 (ru) 2011-08-30
JP2014040426A (ja) 2014-03-06
WO2010002777A3 (en) 2010-06-24
CA2729703A1 (en) 2010-01-07
ECSP11010744A (es) 2011-02-28
CR20110057A (es) 2013-01-25
TW201422609A (zh) 2014-06-16
US8921550B2 (en) 2014-12-30
TW201018668A (en) 2010-05-16
CL2010001639A1 (es) 2011-06-24
SV2011003789A (es) 2011-04-08
AU2009267159A1 (en) 2010-01-07
MX2011000081A (es) 2011-03-02
IL210213A (en) 2015-08-31
PE20140592A1 (es) 2014-05-16

Similar Documents

Publication Publication Date Title
CO6341626A2 (es) Proceso para la preparacion de derivados de benzoimidazol-2-il pirimidina
AR103222A1 (es) Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
AR059380A1 (es) Benzoimidazol-2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina, composiciones farmaceuticas
PE20190437A1 (es) Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo
AR081627A1 (es) Compuestos heterociclicos de nitrogeno insaturados utiles como inhibidores de pde10
AR094262A1 (es) Compuestos antivirales para el tratamiento de la hepatitis c
AR085316A1 (es) Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas
PE20180117A1 (es) Inhibidores de indolamina-2,3-dioxigenasa para el tratamiento de cancer
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20142340A1 (es) Inhibidores de bromodominios
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
PE20142148A1 (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
AR082699A1 (es) Sales de fenotiazindiaminio, composicion farmaceutica en base al compuesto y proceso de preparacion del compuesto
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20161443A1 (es) Compuestos
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR084706A1 (es) Derivados sustituidos de imidazoquinolinas como inhibidores de quinasa y proceso para su preparacion
PE20181272A1 (es) Heterociclilaminas como inhibidores de pi3k
RU2015121431A (ru) Замещенные производные индол-5-ола и их терапевтическое применение
AR070520A1 (es) Derivados de azuleno nitrogenados,composiciones farmaceuticas que los contienen,proceso de preparacion y usos de los mismos para tratar trastornos metabolicos y digestivos,entre otros.
AR056191A1 (es) Anillo de nucleosidos de siete miembros como inhibidores de la replica viral, metodos para su sintesis, composiciones farmaceuticas que los contienen y su uso en el tratamiento de infecciones con virus de la familia flaviviridae
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
CO6341560A2 (es) Proceso para la preparacion de derivados de pirimidina sustituidos.
AR075951A1 (es) Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek
AR077364A1 (es) Derivados de 6-oxo-1,6- dihidro -pirimidin-2-il-) amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)

Legal Events

Date Code Title Description
FC Application refused